Report : Middle East & Africa Gastroparesis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Idiopathic, Diabetic, Post-Surgical, and Others), Drug Class (Prokinetic Agents, Botulinum Toxin Injections, and Antiemetic Agents), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others)

Diabetic Segment is Expected to be Fastest Growing During the Forecast Period for MEA Region

According to a new market research study on “MEA Gastroparesis Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Type, Drug Class, and Distribution Channel” is expected to reach US$ 278.36 million by 2027 from 230.20 US$ million in 2020. The market is estimated to grow at a CAGR of 2.8% from 2020 to 2027. The report provides trends prevailing in the MEA gastroparesis market along with the drivers and restraints pertaining to the market growth. Gastric electrical stimulation therapy research getting more attention is the major factor driving the growth of the MEA gastroparesis market. However, issues associated with aftereffects of gastroparesis drugs hinders the growth of MEA gastroparesis market.      

 The MEA gastroparesis market is segmented on the basis of type, drug class, distribution channel, and country. The MEA gastroparesis market, by type, is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019. The MEA gastroparesis market, by drug class type, is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment held the largest share of the market in 2019. Based on distribution channel, the MEA gastroparesis market is segmented into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019. Based on country, the MEA gastroparesis market is segmented into Saudi Arabia, South Africa, UAE, and rest of MEA. Saudi Arabia held the largest market share in 2019.    

The COVID-19 has shown substantial effects in MEA. The COVID-19 pandemic has caused massive disruptions to global supply chains and affected the research and development activities in these countries in 2020. The companies are preferring non-physical marketing campaigns and shifting sales processes online. The COVID-19 has affected the sales of essential OTC drugs such as anti-emetic and prokinetic drugs. Moreover, the exports and imports of pharmaceutical products are returning to their original momentum. Thus, the availability of the products in the region is improving. Therefore, the growth in African pharmaceuticals is likely to boost the development of the anti-emetic drugs in market. For instance, in May 2020, the Vice president of global health stated in a blog post of Africa program, “The African Medicines Agency (AMA), a continental effort to harmonize medicines regulation, should be fully approved and rapidly scaled up to advance regulatory dependence, mutual recognition, and risk-based regulatory practices. The AMA will also help and support in the production of active ingredients in Africa, streamline market access, and reduce barriers to market entry for manufacturers.

 Allergan Plc; ANI Pharmaceuticals, Inc.; Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.); Ipca Laboratories Ltd.; Johnson and Johnson Services, Inc.; Pfizer Inc.; and TEVA PHARMACEUTICAL INDUSTRIES LTD are among the leading companies in the MEA gastroparesis market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.     

Contact Us
Contact Person: Sameer Joshi 

Phone: +1-646-491-9876
Email Id: 

Download Free PDF Brochure